Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Cantuaria, Guilherme

Northside Hospital Atlanta
United States

Georgia NCI Community Oncology Research Program (GA NCORP) 3UG1CA189997-11S1 Vanessa A. White, M.P.H.
Cantuaria, Guilherme

Northside Hospital Atlanta
United States

Georgia NCI Community Oncology Research Program (GA NCORP) 3UG1CA189997-11S1 Vanessa A. White, M.P.H.
Cao, Yin

Washington University
United States

Obesity, sedentary behaviors, and diet quality for prevention and early detection of early-onset colorectal neoplasia 4R37CA246175-06 Asad Umar, D.V.M., Ph.D.
Cao, Shugeng

University Of Hawaii At Hilo
United States

Discovery of novel natural TEAD inhibitors for the chemoprevention of liver tumors 5UG3CA290375-02 Altaf Mohammed, Ph.D.
Cao, Weidan

Ohio State University
United States

Treatment-Related Cardiotoxicity Risk Prediction for Breast Cancer Patients with a Multimodal AI-based System 1R01CA301579-01 Eileen Dimond, R.N., M.S.
Cao, Weidan

Ohio State University
United States

Treatment-Related Cardiotoxicity Risk Prediction for Breast Cancer Patients with a Multimodal AI-based System 1R01CA301579-01 Eileen Dimond, R.N., M.S.
Cao, Yin

Washington University
United States

PROSPECT-Global Consortium and Risk Factor Discovery 3OT2CA297576-01S1 Asad Umar, D.V.M., Ph.D.
Carlson, Jay W

Ozark Health Ventures, Llc
United States

Ozark Health Ventures LLC dba Cancer Research for the Ozarks (CRO) 3UG1CA189822-11S1 Vanessa A. White, M.P.H.
Carlson, Jay W

Ozark Health Ventures, Llc
United States

Ozark Health Ventures LLC dba Cancer Research for the Ozarks (CRO) 3UG1CA189822-11S1 Vanessa A. White, M.P.H.
Carson, Tiffany Lashaun

H. Lee Moffitt Cancer Ctr & Res Inst
United States

Determining the structural- and functional-level effects of diet-specific interventions on the gut microbiota of a diverse sample of Southern United States adults 5R01CA253219-06 Young Kim, Ph.D.
Castilla, Lucio H.

Univ Of Massachusetts Med Sch Worcester
United States

Study of tyrosine kinase inhibitors as preventive therapy in RUNX1-FPD 1U01CA296350-01 Marjorie Perloff, M.D.
Castro, Cesar M

Massachusetts General Hospital
United States

Composing CODAs to cervical cancer screening through an integrated CRISPR and fluorescent nucleic acid approach 3U01CA279858-03S2 Christos Patriotis, Ph.D., M.Sc.
Caulin, Carlos

University Of Arizona
United States

Genetic Alterations That Confer High Risk to Oral Premalignant Lesions 5R01CA274857-04
Caywood, Emi H

Nemours Children'S Hospital, Delaware
United States

Nemours NCI Community Oncology Research Program (NCORP) 3UG1CA189958-11S1 Vanessa A. White, M.P.H.
Caywood, Emi H

Nemours Children'S Hospital, Delaware
United States

Nemours NCI Community Oncology Research Program (NCORP) 3UG1CA189958-11S1 Vanessa A. White, M.P.H.